MRKRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Marker Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$1.20+0.16 (+15.38%)
Close on Oct 19, 2026
- Market cap
- $23.18M
- P/E (TTM)
- –
- Dividend yield
- –
Marker Therapeutics, Inc. revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Grant income | $3.55M | $6.59M | $3.31M | $3.51M | $1.24M | $466.79K | $213.19K | $205.99K | $183.06K | 100.0% | -46.2% |
| CPRIT AML | $900.01K | $4.41M | – | – | – | – | – | – | – | 25.4% | -79.6% |
| SBIR lymphoma grant | $665.00K | $665.00K | – | – | – | – | – | – | – | 18.7% | 0.0% |
| CPRIT Pancreatic Grant | $573.99K | – | – | – | – | – | – | – | – | 16.2% | – |
| SBIR AML | $472.21K | $982.18K | $200.00K | – | – | – | – | – | – | 13.3% | -51.9% |
| SBIR pancreatic cancer grant | $425.67K | $7.18K | – | – | – | – | – | – | – | 12.0% | +5831.0% |
| National Institutes of Health National - Cancer Institute Grant | $391.31K | $5.82K | – | – | – | – | – | – | – | 11.0% | +6621.1% |
| FDA Grant | $118.48K | $519.75K | $400.00K | $100.00K | – | – | – | – | – | 3.3% | -77.2% |
| Service Revenue | – | – | – | $5.50M | – | – | – | – | – | – | – |
| CPRIT grant | – | $200.00K | $2.70M | $3.40M | – | – | – | – | – | – | – |
| Additional CPRIT grant | – | $0 | – | – | – | – | – | – | – | – | – |
By region
From the segment and revenue-disaggregation notes of Marker Therapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.